Jazz Pharmaceuticals (NASDAQ:JAZZ) Hits New 1-Year Low at $103.01

Jazz Pharmaceuticals plc (NASDAQ:JAZZ)’s stock price reached a new 52-week low on Thursday . The stock traded as low as $103.01 and last traded at $107.02, with a volume of 161874 shares trading hands. The stock had previously closed at $110.31.

Analysts Set New Price Targets

JAZZ has been the topic of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating and set a $180.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $222.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday. Stifel Nicolaus boosted their price objective on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a report on Friday, March 15th. Barclays cut their price target on Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Truist Financial reiterated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $192.75.

Jazz Pharmaceuticals Trading Up 0.7 %

The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.85 and a current ratio of 2.27. The business has a fifty day simple moving average of $116.44 and a 200 day simple moving average of $121.10. The company has a market cap of $6.94 billion, a P/E ratio of 22.68, a P/E/G ratio of 1.51 and a beta of 0.63.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.01 billion. Analysts anticipate that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CAO Patricia Carr sold 1,936 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CAO Patricia Carr sold 1,936 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Philip L. Johnson purchased 12,000 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was bought at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the acquisition, the chief financial officer now owns 27,932 shares in the company, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. Company insiders own 4.40% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Several large investors have recently added to or reduced their stakes in JAZZ. Vestal Point Capital LP acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at approximately $89,175,000. Armistice Capital LLC increased its position in Jazz Pharmaceuticals by 108.4% in the 4th quarter. Armistice Capital LLC now owns 651,626 shares of the specialty pharmaceutical company’s stock valued at $80,150,000 after acquiring an additional 338,882 shares during the period. Los Angeles Capital Management LLC increased its position in Jazz Pharmaceuticals by 558.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 322,775 shares of the specialty pharmaceutical company’s stock valued at $41,780,000 after acquiring an additional 273,764 shares during the period. Pacer Advisors Inc. increased its position in Jazz Pharmaceuticals by 28.1% in the 4th quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock valued at $125,916,000 after acquiring an additional 224,865 shares during the period. Finally, Thompson Siegel & Walmsley LLC increased its position in Jazz Pharmaceuticals by 242.8% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 270,574 shares of the specialty pharmaceutical company’s stock valued at $35,023,000 after acquiring an additional 191,648 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.